Phio Pharmaceuticals Corp. announced its third quarter 2025 financial results and provided a business update. The company reported progress in its Phase 1b clinical trial of INTASYL PH-762 for skin cancer, advancing to the fifth and final cohort at the maximum dose. At this dose, one patient achieved 100% tumor clearance (complete response), a second patient had greater than 90% tumor clearance (near complete response), and a third patient showed greater than 50% tumor clearance (partial response). No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed, and PH-762 was well tolerated across all dose cohorts. The Safety Monitoring Committee issued a favorable review of safety data at the maximum dose. In addition, Phio completed a warrant inducement financing in November 2025, securing expected net proceeds of approximately $12.1 million, extending the company's cash runway into the first half of 2027. The company also highlighted recent scientific and investor presentations related to its INTASYL siRNA technology and ongoing clinical developments.